Cargando…

Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis

BACKGROUND: Health-related quality of life (HRQoL) captures different aspects of the fibrotic interstitial lung disease (FILD) evaluation from the patient’s perspective. However, little is known about how HRQoL changes in patients with non-idiopathic pulmonary fibrosis (IPF) FILD, especially in thos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takei, Reoto, Matsuda, Toshiaki, Fukihara, Jun, Sasano, Hajime, Yamano, Yasuhiko, Yokoyama, Toshiki, Kataoka, Kensuke, Kimura, Tomoki, Suzuki, Atsushi, Furukawa, Taiki, Fukuoka, Junya, Johkoh, Takeshi, Kondoh, Yasuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347395/ https://www.ncbi.nlm.nih.gov/pubmed/37457568 http://dx.doi.org/10.3389/fmed.2023.1067149

Ejemplares similares

Acute exacerbation of idiopathic pulmonary fibrosis after SARS-CoV-2 vaccination
por: Bando, Tomohiro, et al.
Publicado: (2022)

Hemosiderin-laden macrophages are an independent factor correlated with pulmonary vascular resistance in idiopathic pulmonary fibrosis: a case control study
por: Fukihara, Jun, et al.
Publicado: (2017)

Anti‐MDA5 antibody‐positive clinically amyopathic dermatomyositis with diffuse alveolar damage diagnosed by transbronchial lung cryobiopsy: A case report
por: Ishihara, Hiroyuki, et al.
Publicado: (2021)

Two cases of acute respiratory failure following SARS‐CoV‐2 vaccination in post‐COVID‐19 pneumonia
por: Bando, Tomohiro, et al.
Publicado: (2022)

Acute exacerbation of idiopathic pulmonary fibrosis triggered by Aspergillus empyema
por: Suzuki, Atsushi, et al.
Publicado: (2018)

A Volumetric Computed Tomography Analysis of the Normal Lung in Idiopathic Pulmonary Fibrosis: The Relationship with the Survival
por: Ohkubo, Hirotsugu, et al.
Publicado: (2017)

Histologic factors associated with nintedanib efficacy in patients with idiopathic pulmonary fibrosis
por: Nemoto, Masahiro, et al.
Publicado: (2021)

Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting
por: Mutoh, Yoshikazu, et al.
Publicado: (2023)

Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer: A retrospective observational study
por: Oi, Hajime, et al.
Publicado: (2022)

Mesalazine-induced lung injury with severe respiratory failure successfully treated with steroids and non-invasive positive pressure ventilation
por: Oi, Hajime, et al.
Publicado: (2020)

Depression Is Significantly Associated with the Health Status in Patients with Idiopathic Pulmonary Fibrosis
por: Matsuda, Toshiaki, et al.
Publicado: (2017)

Effectiveness of monoclonal antibody therapy for COVID-19 patients using a risk scoring system
por: Mutoh, Yoshikazu, et al.
Publicado: (2022)

The St. George’s Respiratory Questionnaire as a prognostic factor in IPF
por: Furukawa, Taiki, et al.
Publicado: (2017)

Effect of the 2020 hypersensitivity pneumonitis guideline on the pathologic diagnosis of interstitial pneumonia
por: Ozasa, Mutsumi, et al.
Publicado: (2023)

Sensitivity of transbronchial lung cryobiopsy in the diagnosis of different interstitial lung diseases
por: Zaizen, Yoshiaki, et al.
Publicado: (2022)

Endobronchial Ultrasonography with a Guide Sheath Transbronchial Biopsy for Diagnosing Peripheral Pulmonary Lesions within or near Fibrotic Lesions in Patients with Interstitial Lung Disease
por: Ito, Takayasu, et al.
Publicado: (2021)

Combined pulmonary fibrosis and emphysema with myeloperoxidase-antineutrophil cytoplasmic antibody positivity that resolved upon smoking cessation
por: Nemoto, Masahiro, et al.
Publicado: (2018)

Early decrease in erector spinae muscle area and future risk of mortality in idiopathic pulmonary fibrosis
por: Nakano, Akiko, et al.
Publicado: (2020)

The impact of high-flow nasal cannula oxygen therapy on exercise capacity in fibrotic interstitial lung disease: a proof-of-concept randomized controlled crossover trial
por: Suzuki, Atsushi, et al.
Publicado: (2020)

The In Vivo Fibrotic Role of FIZZ1 in Pulmonary Fibrosis
por: Liu, Tianju, et al.
Publicado: (2014)

Proposed method of histological separation between connective tissue disease-associated interstitial pneumonia and idiopathic interstitial pneumonias
por: Ozasa, Mutsumi, et al.
Publicado: (2018)

Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity
por: Sato, Seidai, et al.
Publicado: (2017)

Significance of Pulmonary Arterial Pressure as a Prognostic Indicator in Lung-Dominant Connective Tissue Disease
por: Suzuki, Atsushi, et al.
Publicado: (2014)

Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis
por: Nishiyama, Osamu, et al.
Publicado: (2021)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
por: Collins, Bridget F., et al.
Publicado: (2019)

Disease progression in idiopathic pulmonary fibrosis under anti-fibrotic treatment
por: Cilli, Aykut, et al.
Publicado: (2023)

Pulmonary vascular volume is associated with DLCO and fibrotic score in idiopathic pulmonary fibrosis: an observational study
por: Wu, Wen-Jui, et al.
Publicado: (2022)

Early corticosteroid dose tapering in patients with acute exacerbation of idiopathic pulmonary fibrosis
por: Anan, Keisuke, et al.
Publicado: (2022)

Converging pathways in pulmonary fibrosis and Covid-19 - The fibrotic link to disease severity
por: Wigén, Jenny, et al.
Publicado: (2020)

Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
por: Dempsey, Timothy M., et al.
Publicado: (2022)

Macrophage-derived GPNMB trapped by fibrotic extracellular matrix promotes pulmonary fibrosis
por: Wang, Jing, et al.
Publicado: (2023)

Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis
por: Astor, Todd L., et al.
Publicado: (2023)

MIXTURE of human expertise and deep learning—developing an explainable model for predicting pathological diagnosis and survival in patients with interstitial lung disease
por: Uegami, Wataru, et al.
Publicado: (2022)

Correction: Early corticosteroid dose tapering in patients with acute exacerbation of idiopathic pulmonary fibrosis
por: Anan, Keisuke, et al.
Publicado: (2023)

Pathological and radiological correlation in an autopsy case of combined pulmonary fibrosis and emphysema
por: Karata, Hiroki, et al.
Publicado: (2015)

Stepwise diagnostic algorithm for high-attenuation pulmonary abnormalities on CT
por: Fukuda, Taiki, et al.
Publicado: (2023)

The Anti-fibrotic Effects and Mechanisms of MicroRNA-486-5p in Pulmonary Fibrosis
por: Ji, Xiaoming, et al.
Publicado: (2015)

The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs
por: Shen, Hao, et al.
Publicado: (2022)

Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation
por: Sakızcı Uyar, Bahar, et al.
Publicado: (2022)

Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
por: Khor, Yet H., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bh45l0ohr45gfmo7hec755ion6